{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:45:16Z","timestamp":1788090316359,"version":"build-2803163510"},"reference-count":16,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dam Med J"],"abstract":"<jats:p>INTRODUCTION. Third-generation aromatase inhibitors (AIs) are the cornerstone of the management of hormone receptor-positive breast cancer. Annually, approximately 4,700 Danish women are diagnosed with breast cancer. A large number of patients treated with long-term AI experience arthralgias and myalgias, described in the literature as AI-induced musculoskeletal symptoms (AIMSS). This report aims to summarise the existing knowledge on the syndrome and present cases of AIMSS referred with refractory foot pain to raise awareness of the syndrome as a diagnostic pitfall.\n\nMETHODS. In this study, the electronic patient journals of five potential cases of AIMSS were examined. The patients were all Caucasian females with breast cancer receiving treatment with anti-oestrogenic medication.\n\nRESULTS. AIMSS was found to be the most probable explanation in all five cases. AI-associated musculoskeletal syndrome is reported in 30-70% of patients in AI treatment. Among the five summarised cases, no clinically relevant additional information was gained from extensive imaging. The symptoms led to surgery at our department, in one case with no effect.\n\nCONCLUSIONS. AIMSS may affect all joints, including the ankles and feet. Lack of patient information regarding AIMSS can lead to unnecessary, time-consuming, costly and potentially harmful diagnostic procedures and treatment.\n\nFUNDING. None.\n\nTRIAL REGISTRATION. Not relevant.<\/jats:p>","DOI":"10.61409\/a06250469","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T12:23:11Z","timestamp":1768220591000},"page":"1-6","source":"Crossref","is-referenced-by-count":1,"title":["Aromatase inhibitor-induced musculoskeletal symptoms in foot and ankle surgery"],"prefix":"10.61409","author":[{"given":"Sara","family":"Woldu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bjerre-Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth Chukwuemeka","family":"Obionu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"40208","published-online":{"date-parts":[[2025,12]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Ibfelt EH, Jensen H, Offersen BV, et al. Diagnosis and treatment of breast cancer in Denmark during the COVID-19 pandemic: a nationwide population-based study. Acta Oncol. 2023;62(12):1749-1756. https:\/\/doi.org\/10.1080\/0284186X.2023.2259598","DOI":"10.1080\/0284186X.2023.2259598"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results Database. Breast Cancer Res Treat. 2002;76(1):27-36 https:\/\/doi.org\/10.1023\/A:1020299707510","DOI":"10.1023\/A:1020299707510"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Wu VS, Kanaya N, Lo C, et al. From bench to bedside: what do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer? J Steroid Biochem Mol Biol. 2015;153:45-53. https:\/\/doi.org\/10.1016\/j.jsbmb.2015.05.005","DOI":"10.1016\/j.jsbmb.2015.05.005"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Hyder T, Marino CC, Ahmad S, et al. Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management. Front Endocrinol (Lausanne). 2021;12:713700. https:\/\/doi.org\/10.3389\/fendo.2021.713700","DOI":"10.3389\/fendo.2021.713700"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Bekes I, Huober J. Extended adjuvant endocrine therapy in early breast cancer patients - review and perspectives. Cancers (Basel). 2023;15(16):4190. https:\/\/doi.org\/10.3390\/cancers15164190","DOI":"10.3390\/cancers15164190"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Camejo N, Castillo C, Santana D, et al. Arthralgia and myalgia associated with aromatase inhibitors: frequency and characterization in real-life patients. Ecancermedicalscience. 2024;18:1697. https:\/\/doi.org\/10.3332\/ecancer.2024.1697","DOI":"10.3332\/ecancer.2024.1697"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Zhu Y, Loggia ML, Edwards RR, et al. Increased clinical pain locations and pain sensitivity in women after breast cancer surgery: influence of aromatase inhibitor therapy. Clin J Pain. 2022;38(12):721-729. https:\/\/doi.org\/10.1097\/AJP.0000000000001073","DOI":"10.1097\/AJP.0000000000001073"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Wright VJ, Schwartzman JD, Itinoche R, et al. The musculoskeletal syndrome of menopause. Climacteric. 2024;27(5):466-472. https:\/\/doi.org\/10.1080\/13697137.2024.2380363","DOI":"10.1080\/13697137.2024.2380363"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Kosmidis PA, Deligianni E, Kosmidis T. 247P usage and side effects of each common aromatase inhibitor in 5 large European countries: real-world data analysis. Ann Oncol. 2022;33(suppl 3):S236. https:\/\/doi.org\/10.1016\/j.annonc.2022.03.269","DOI":"10.1016\/j.annonc.2022.03.269"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Zhang Y, Zhao L, Liu Y, et al. Adverse event profiles of the third-generation aromatase inhibitors: analysis of spontaneous reports submitted to FAERS. Biomedicines. 2024;12(8):1708. https:\/\/doi.org\/10.3390\/biomedicines12081708","DOI":"10.3390\/biomedicines12081708"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Mao JJ, Stricker C, Bruner D, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer. 2009;115(16):3631-3639. https:\/\/doi.org\/10.1002\/cncr.24419","DOI":"10.1002\/cncr.24419"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007;25(25):3797-3799. https:\/\/doi.org\/10.1200\/JCO.2007.11.9529","DOI":"10.1200\/JCO.2007.11.9529"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Shanmugam VK, McCloskey J, Elston B, et al. The CIRAS study: a case-control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms. Breast Cancer Res Treat. 2012;131(2):699-708. https:\/\/doi.org\/10.1007\/s10549-011-1849-8","DOI":"10.1007\/s10549-011-1849-8"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Niravath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol. 2013;24(6):1443-1449. https:\/\/doi.org\/10.1093\/annonc\/mdt037","DOI":"10.1093\/annonc\/mdt037"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Roberts KE, Adsett IT, Rickett K, et al. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer. Cochrane Database Syst Rev. 2022;1(1):CD013167. https:\/\/doi.org\/10.1002\/14651858.CD013167.pub2","DOI":"10.1002\/14651858.CD013167.pub2"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Henry NL, Giles JT, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008;111(2):365-372. https:\/\/doi.org\/10.1007\/s10549-007-9774-6","DOI":"10.1007\/s10549-007-9774-6"}],"container-title":["Danish Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:15:06Z","timestamp":1769523306000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/dmj\/A06250469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":16,"URL":"https:\/\/doi.org\/10.61409\/a06250469","relation":{},"ISSN":["2245-1919"],"issn-type":[{"value":"2245-1919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}